Opportunities Preloader

Please Wait.....

Report

Europe Pingueculum Drugs Market - Industry Trends and Forecast to 2029

Market Report I 2022-11-01 I 239 Pages I Data Bridge Market Research

The Europe pingueculum drugs market is projected to register a substantial CAGR of 5.9% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation:
Europe Pingueculum Drugs Market, By Treatment (Artificial Tears /Topical Lubricants, Steroid Eye Drops, Non-steroidal Anti Inflammatory Drops, and Others), Formulation Type (Eye Drops, Eye Ointments, and Others), Mode of Purchase (Prescription, Over the Counter), Drug Type (Branded, Generics), Population Type (Geriatric, Adults), End User (Hospitals, Speciality Clinics, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, and Rest of Europe) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Europe pingueculum drug market are:
- Rise in the prevalence of pingueculum disease around the globe
- Rise in the UV exposure to the individuals due to ozone defect casing pingueculum more frequent
Market Players:

Some of the major players operating in the Europe pingueculum drugs market are:

- Akorn Operating Company LLC
- Alcon Inc.
- Amneal Pharmaceuticals LLC
- Bausch & Lomb Incorporated
- Bayer AG
- Johnson & Johnson Consumer Inc.
- Novartis AG
- OASIS Medical, Inc.
- SAGER PHARMA
- Santen Pharmaceutical Co.
- Johnson & Johnson Vision Care, Inc.
- Similasan Corporation
- Sylentis
- Laboratoires Thea
- Wellona Pharma
- Zydus Group

TABLE OF CONTENTS
1 INTRODUCTION 43
1.1 OBJECTIVES OF THE STUDY 43
1.2 MARKET DEFINITION 43
1.3 OVERVIEW OF THE EUROPE PINGUECULUM DRUGS MARKET 43
1.4 CURRENCY AND PRICING 45
1.5 LIMITATIONS 45
1.6 MARKETS COVERED 46
2 EUROPE PINGUECULUM DRUGS MARKET: SEGMENTATION 48
2.1 MARKETS COVERED 48
2.2 GEOGRAPHICAL SCOPE 49
2.3 YEARS CONSIDERED FOR THE STUDY 50
2.4 CURRENCY AND PRICING 50
2.5 DBMR TRIPOD DATA VALIDATION MODEL 51
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 54
2.7 MULTIVARIATE MODELLING 55
2.8 TREATMENT LIFELINE CURVE 55
2.9 DBMR MARKET POSITION GRID 56
2.10 VENDOR SHARE ANALYSIS 58
2.11 MARKET END-USER COVERAGE GRID 59
2.12 SECONDARY SOURCES 60
2.13 ASSUMPTIONS 60
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 64
4.1 EPIDERMIOLOGY 65
4.2 PESTEL ANALYSIS 66
4.3 PORTER'S FIVE FORCES 67
4.4 PIPELINE ANALYSIS FOR THE EUROPE PINGUECULUM DRUGS MARKET 68
4.5 INDUSTRIAL INSIGHTS: 69
4.6 CONCLUSION: 69
5 EUROPE PINGUECULUM DRUGS MARKET: REGULATIONS 70
6 MARKET OVERVIEW 73
6.1 DRIVERS 75
6.1.1 RISING PREVALENCE OF PINGUECELA DISORDERS AND OCULAR PAINS 75
6.1.2 RISE IN THE CHRONIC UV RADIATION EXPOSURE DUE TO OZONE DEFECT 75
6.1.3 INCREASING AWARENESS AMONG PEOPLE FOR EYE-RELATED DISEASES 76
6.1.4 RISING OPHTHALMIC EMERGENCIES IN THE GERIATRIC PATIENT 77
6.2 RESTRAINTS 77
6.2.1 STRINGENT RULES & REGULATIONS 77
6.2.2 LACK OF HEALTHCARE FACILITIES FOR EYE TREATMENT 78
6.3 OPPORTUNITIES 79
6.3.1 INITIATIVES AND PLANS TO LESSEN THE PREVALENCE OF EYE ILLNESSES 79
6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 79
6.3.3 INCREASE IN HEALTHCARE SPENDING AND ACCESSIBLE INCOME 80
6.4 CHALLENGES 81
6.4.1 ADVERSE EFFECTS OF STEROID EYE DROPS 81
6.4.2 LACK OF SKILLED OPHTHALMOLOGISTS 82
7 EUROPE PINGUECULUM DRUGS MARKET, BY TREATMENT 83
7.1 OVERVIEW 84
7.2 ARTIFICIAL TEARS/TOPICAL LUBRICANTS 87
7.2.1 DEMULCENT 87
7.2.2 EMOLLIENTS 87
7.3 STEROID EYE DROPS 88
7.3.1 KETONE STEROIDS 89
7.3.1.1 PREDNISOLONE 89
7.3.1.2 DEXAMETHASONE 89
7.3.1.3 FLUROMETHOLONE 89
7.3.1.4 MEDRYSONE 89
7.3.1.5 RIMEXOLONE 89
7.3.1.6 OTHERS 89
7.3.2 ESTER STEROID (LOTERPREDNOL) 90
7.4 NON-STEROIDAL ANTI-INFLAMMATORY DROPS 90
7.5 OTHERS 90
8 EUROPE PINGUECULUM DRUGS MARKET, BY FORMULATION 91
8.1 OVERVIEW 92
8.2 EYE DROPS 95
8.2.1 EYE DROPS WITH PRESERVATIVES 95
8.2.2 PRESERVATIVE-FREE EYE DROPS 95
8.3 EYE OINTMENTS 96
8.3.1 WITH PRESERVATIVES 96
8.3.2 PRESERVATIVE-FREE 96
8.3.3 OTHERS 96
8.4 OTHERS 97
9 EUROPE PINGUECULUM DRUGS MARKET, MODE OF PURCHASE 98
9.1 OVERVIEW 99
9.2 PRESCRIPTION 102
9.3 OVER THE COUNTER (OTC) 102
10 EUROPE PINGUECULUM DRUGS MARKET, BY DRUGS TYPE 103
10.1 OVERVIEW 104
10.2 BRANDED 107
10.3 GENERICS 107
11 EUROPE PINGUECULUM DRUGS MARKET, BY POPULATION TYPE 108
11.1 OVERVIEW 109
11.2 GERIATRIC 112
11.2.1 MALE 112
11.2.2 FEMALE 112
11.3 ADULTS 113
11.3.1 MALE 113
11.3.2 FEMALE 113
12 EUROPE PINGUECULUM DRUGS MARKET, BY END USER 114
12.1 OVERVIEW 115
12.2 HOSPITALS 118
12.3 SPECIALTY CLINICS 118
12.4 HOME HEALTHCARE 119
12.5 OTHERS 119
13 EUROPE PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL 120
13.1 OVERVIEW 121
13.2 RETAIL PHARMACIES 124
13.3 HOSPITAL PHARMACIES 124
13.4 ONLINE PHARMACIES 125
13.5 OTHERS 125
14 EUROPE PINGUECULUM DRUGS MARKET, BY REGION 126
14.1 EUROPE 127
14.1.1 SPAIN 136
14.1.2 RUSSIA 140
14.1.3 TURKEY 144
14.1.4 GERMANY 148
14.1.5 ITALY 152
14.1.6 U.K. 156
14.1.7 FRANCE 160
14.1.8 HUNGARY 164
14.1.9 AUSTRIA 168
14.1.10 SWITZERLAND 172
14.1.11 NETHERLANDS 176
14.1.12 POLAND 180
14.1.13 IRELAND 184
14.1.14 NORWAY 188
14.1.15 LITHUANIA 192
14.1.16 REST OF EUROPE 196
15 EUROPE PINGUECULUM DRUGS MARKET: COMPANY LANDSCAPE 197
15.1 COMPANY SHARE ANALYSIS: EUROPE 197
16 SWOT ANALYSIS 198
17 COMPANY PROFILE 199
17.1 ALCON INC. 199
17.1.1 COMPANY SNAPSHOT 199
17.1.2 REVENUE ANALYSIS 199
17.1.3 COMPANY SHARE ANALYSIS 200
17.1.4 PRODUCT PORTFOLIO 200
17.1.5 RECENT DEVELOPMENT 200
17.2 ABBVIE INC. 201
17.2.1 COMPANY SNAPSHOT 201
17.2.2 REVENUE ANALYSIS 201
17.2.3 COMPANY SHARE ANALYSIS 202
17.2.4 PRODUCT PORTFOLIO 202
17.2.5 RECENT DEVELOPMENT 203
17.3 BAUSCH & LOMB INCORPORATED 204
17.3.1 COMPANY SNAPSHOT 204
17.3.2 REVENUE ANALYSIS 204
17.3.3 COMPANY SHARE ANALYSIS 205
17.3.4 PRODUCT PORTFOLIO 205
17.3.5 RECENT DEVELOPMENT 206
17.4 BAYER AG 207
17.4.1 COMPANY SNAPSHOT 207
17.4.2 REVENUE ANALYSIS 207
17.4.3 COMPANY SHARE ANALYSIS 208
17.4.4 PRODUCT PORTFOLIO 208
17.4.5 RECENT DEVELOPMENTS 208
17.5 JOHNSON & JOHNSON VISION CARE, INC. 209
17.5.1 COMPANY SNAPSHOT 209
17.5.2 REVENUE ANALYSIS 209
17.5.3 COMPANY SHARE ANALYSIS 210
17.5.4 PRODUCT PORTFOLIO 210
17.5.5 RECENT DEVELOPMENT 210
17.6 AKORN OPERATING COMPANY LLC 211
17.6.1 COMPANY SNAPSHOT 211
17.6.2 . PRODUCT PORTFOLIO 211
17.6.3 RECENT DEVELOPMENT 211
17.7 AMNEAL PHARMACEUTICALS LLC. 212
17.7.1 COMPANY SNAPSHOT 212
17.7.2 REVENUE ANALYSIS 212
17.7.3 PRODUCT PORTFOLIO 213
17.7.4 RECENT DEVELOPMENTS 213
17.8 EYERIS VISIONCARE PVT. LTD. 214
17.8.1 COMPANY SNAPSHOT 214
17.8.2 PRODUCT PORTFOLIO 214
17.8.3 RECENT DEVELOPMENTS 215
17.9 LABORATOIRES THEA 216
17.9.1 COMPANY SNAPSHOT 216
17.9.2 PRODUCT PORTFOLIO 216
17.9.3 RECENT DEVELOPMENT 217
17.10 MAYA BIOTECH PRIVATE LIMITED 218
17.10.1 COMPANY SNAPSHOT 218
17.10.2 PRODUCT PORTFOLIO 218
17.10.3 RECENT DEVELOPMENTS 219
17.11 NOVARTIS AG 220
17.11.1 COMPANY SNAPSHOT 220
17.11.2 REVENUE ANALYSIS 220
17.11.3 PRODUCT PORTFOLIO 221
17.11.4 RECENT DEVELOPMENT 221
17.12 OASIS MEDICAL, INC. 222
17.12.1 COMPANY SNAPSHOT 222
17.12.2 PRODUCT PORTFOLIO 222
17.12.3 RECENT DEVELOPMENT 222
17.13 PRESTIGE CONSUMER HEALTHCARE, INC. 223
17.13.1 COMPANY SNAPSHOT 223
17.13.2 PRODUCT PORTFOLIO 224
17.13.3 RECENT DEVELOPMENT 224
17.14 SAGER PHARMA 225
17.14.1 COMPANY SNAPSHOT 225
17.14.2 PRODUCT PORTFOLIO 225
17.14.3 RECENT DEVELOPMENTS 225
17.15 SANTEN PHARMACEUTICAL CO., LTD. 226
17.15.1 COMPANY SNAPSHOT 226
17.15.2 REVENUE ANALYSIS 226
17.15.3 PRODUCT PORTFOLIO 227
17.15.4 RECENT DEVELOPMENTS 227
17.16 SIMILASAN CORPORATION 228
17.16.1 COMPANY SNAPSHOT 228
17.16.2 PRODUCT PORTFOLIO 228
17.16.3 RECENT DEVELOPMENTS 228
17.17 SPECTRA VISION CARE 229
17.17.1 COMPANY SNAPSHOT 229
17.17.2 PRODUCT PORTFOLIO 229
17.17.3 RECENT DEVELOPMENTS 230
17.18 SYLENTIS 231
17.18.1 COMPANY SNAPSHOT 231
17.18.2 PRODUCT PORTFOLIO 231
17.18.3 RECENT DEVELOPMENTS 231
17.19 WELLONA PHARMA 232
17.19.1 COMPANY SNAPSHOT 232
17.19.2 PRODUCT PORTFOLIO 232
17.19.3 RECENT DEVELOPMENTS 232
17.20 ZYDUS GROUP 233
17.20.1 COMPANY SNAPSHOT 233
17.20.2 REVENUE ANALYSIS 233
17.20.3 PRODUCT PORTFOLIO 234
17.20.4 RECENT DEVELOPMENTS 234
18 QUESTIONNAIRE 235
19 RELATED REPORTS 239

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE